Australia Expands PCT Options with EPO and IPOS: International Search Choice Becomes a Strategic Filing Decision

According to recent reporting by Asia IP, and as confirmed by official information released by the relevant authorities, from March 1, 2026, PCT applicants filing through IP Australia may designate the European Patent Office (EPO) or the Intellectual Property Office of Singapore (IPOS) as their International Searching Authority (ISA) and International Preliminary Examining Authority (IPEA), in addition to the previously available options of IP Australia and the Korean authority. For applicants using Australia as the receiving Office, this is more than a procedural update. It materially changes how international filing strategy can be aligned with downstream market priorities.

The practical significance of the new options lies in what each authority may signal for later prosecution. The EPO route is especially attractive for applicants expecting to enter Europe, because where the EPO carries out the international search and also acts for Chapter II examination, the applicant may obtain a 75 percent reduction in the European examination fee at regional phase entry. By contrast, the IPOS option is likely to appeal to applicants who want stronger visibility over Chinese-language prior art at an earlier stage, particularly where R&D, manufacturing, supply chains or future enforcement concerns are closely tied to Asia.

This is not just an expansion of formality, but an earlier strategic fork in the PCT process

On paper, the change looks simple: two more authorities are now available to Australian PCT filers. In practice, however, the decision about ISA and IPEA is becoming a much more consequential strategic choice. Applicants can now use the international phase to make a more deliberate trade-off between later regional cost efficiency, language-specific prior art exposure and the expected logic of prosecution in key jurisdictions. That is a meaningful shift from a model in which many applicants treated authority selection as a largely administrative filing step.

For companies building multi-jurisdiction patent portfolios, the international authority now functions more clearly as an early routing mechanism. The question is no longer only who can search the application, but whose search framework best prepares the application for the commercial regions that matter most. This change will likely matter most for applicants that already link filing decisions to licensing strategy, investment messaging, freedom-to-operate concerns and expected opposition or invalidity risks.

Why the EPO option may become the preferred route for Europe-focused applicants

The appeal of the EPO option is not limited to institutional reputation. Its practical value lies in prosecution continuity. Applicants that foresee European regional phase entry may benefit from having the search and written opinion generated within the same institutional logic that will later shape European examination expectations. Where the EPO also handles Chapter II preliminary examination, the resulting 75 percent reduction in the European examination fee adds a clear economic incentive, especially for applicants managing larger portfolios or trying to allocate budget more tightly across multiple jurisdictions.

That said, the EPO route works best when the European track is identified early. The official framework also indicates that EPO preliminary examination is tied to cases in which the EPO has already acted as ISA. This makes the option particularly suitable for applicants with a defined Europe-first or Europe-important strategy, rather than those still treating Europe as only a remote or contingent filing possibility.

Why IPOS may matter well beyond Singapore itself

The value of IPOS should not be measured only by reference to Singapore as a destination market. Its importance in this new arrangement is broader. Official materials highlight its usefulness for prior art searches involving Chinese-language documents, which may be highly relevant for applicants operating in sectors where technical disclosure, manufacturing know-how, supplier documentation or patenting activity intersects heavily with Chinese-language sources. In those cases, a stronger earlier view of Chinese prior art may improve claim drafting, priority planning and national phase expectations.

There is also a wider regional logic. For applicants whose commercial footprint is concentrated in Asia, or whose enforcement and licensing prospects depend on Asian manufacturing and distribution ecosystems, IPOS may offer a search perspective better aligned with the competitive realities they actually face. That does not mean it will be the best choice in every technology area, but it may prove particularly valuable where language coverage and Asian market intelligence are central to risk assessment.

How applicants should think about the new choices from March 1, 2026 onward

Applicants preparing to file through Australia on or after March 1, 2026 should avoid treating this as a minor technical update. A more disciplined approach is to ask three questions before filing. First, is Europe a serious target for market entry, licensing or investor signalling? Second, is the most relevant prior art likely to include Chinese-language sources? Third, does the applicant want to use the international phase to optimize downstream prosecution cost and positioning rather than merely secure a placeholder filing?

If Europe is central, the EPO route may offer greater procedural and economic alignment. If Chinese-language prior art visibility and Asian competitive monitoring are more important, IPOS may deserve closer attention. And where the case remains exploratory, applicants should still compare the full set of available authorities, including existing options, across quality, language coverage, timing, cost and communication practicalities. More choice in the PCT system creates more flexibility, but only for applicants prepared to convert that flexibility into a coherent filing strategy.